News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Bioheart, Inc. Provides Update: Clinical Studies Strategy and Progress
January 11, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SUNRISE, Fla., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phase 3
MORE ON THIS TOPIC
Pancreatic cancer
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
October 23, 2026
·
4 min read
·
Heather McKenzie
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Immuno-oncology
ESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2
October 23, 2026
·
3 min read
·
Michael Gibney
FDA
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
October 23, 2026
·
3 min read
·
Tristan Manalac
